Shiny K. Kajal/LinkedIn
Mar 3, 2026, 17:04
Shiny K Kajal: Therapeutic Apheresis Is Redefining the Clinical Scope of Transfusion Medicine
Shiny K Kajal, Senior Resident at Adesh University, shared a post on LinkedIn:
“Post 29 – When most people think of transfusion medicine, they think of blood bags and compatibility testing.
But modern Immunohematology and Blood Transfusion goes far beyond that.
Therapeutic Apheresis allows selective removal of disease-causing components directly from circulation – offering rapid clinical benefit in several critical conditions.
Key Apheresis Modalities
- Therapeutic Plasma Exchange (TPE) – Removal of pathogenic plasma components
- Red Cell Exchange – Replacement of abnormal erythrocytes
- Leukapheresis – Rapid cytoreduction in leukocytosis
- Plateletpheresis – Control of extreme thrombocytosis
- LDL Apheresis – Removal of atherogenic lipoproteins
From autoimmune diseases to hematologic emergencies, therapeutic apheresis is redefining the clinical scope of transfusion medicine.
Not just transfusing blood — but therapeutically transforming it.”
Stay updated with Hemostasis Today.
-
Jun 9, 2026, 11:36Chris Boshoff: FDA Approves Our Treatment for Hemophilia A and B for 2 New Patient Populations
-
Jun 9, 2026, 10:52Vaidehi Prasanth: The Role of Viscoelastic Testing in Low- and Middle-Income Countries
-
Jun 9, 2026, 10:37Maria Bruzelius: Hemophilia and Bleeding Disorder in Clinical Practice at NordCoag 2026
-
Jun 9, 2026, 10:02Understanding Factor X Deficiency – ICHCC
-
Jun 9, 2026, 09:49Lee Severin: Why Patients Love Platelet-Rich Plasma
-
Jun 9, 2026, 09:42Lorena Gerlach: Blood Transportation Duty on this Muggy Spring Day
-
Jun 9, 2026, 08:54Shujha Abbas: Understanding the Real Cost of Gene Therapie
-
Jun 9, 2026, 04:47Akshat Jain: Marstacimab Gets FDA Expension for Children with Hemophilia B
-
Jun 9, 2026, 03:30Fayad Al-Haimus: High-Risk Emergencies and Lifelong Learning at CAEP 2026